Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience

Issapour, A., Frank, B., Crook, S., Hite, M. D., Dorn, M. L., Rosenzweig, E. B., Ivy, D. D., & Krishnan, U. S. (2022). Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real‐world experience. Pediatric Pulmonology, 57(3), 724–733. Portico. https://doi.org/10.1002/ppul.25796
Authors:
Azadeh Issapour
Benjamin Frank
Sarah Crook
Michelle D. Hite
Michelle L. Dorn
Erika B. Rosenzweig
D. Dunbar Ivy
Usha S. Krishnan
Affiliated Authors:
Azadeh Issapour
Sarah Crook
Michelle L. Dorn
Erika B. Rosenzweig
Usha S. Krishnan
Columbia Affiliation:
Subjects:
Hypertension, Pulmonary (MeSH)
Phenylpropionates (MeSH)
Pulmonary Arterial Hypertension (MeSH)
Pyridazines (MeSH)
Author Keywords:
ambrisentan
congenital heart disease
endothelin receptor antagonist
hemodynamics
pediatric cardiology
phosphodiesterase 5 inhibitor
pulmonary hypertension
tadalafil
targeted therapy
elink
Publication Type:
Article
Unique ID:
10.1002/ppul.25796
PMID:
34921523
DOI:
10.1002/ppul.25796
Journal:
Pediatric Pulmonology
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View Web of Science Record
View PubMed Record

Record Created: